Takeda California Mobilizes to Support Healthy Living and Combat Diabetes
Employees will be biking to raise funds for the American Diabetes
Association in both San Diego and San Francisco, March 22.
San Diego, San Francisco, CA, US, March 20, 2012 -- Takeda California
scientists and employees are taking a stand for healthy living to combat
diabetes and leading by example with a company-wide bike ride. On March
22, the second annual Tour de Takeda will take place in both San Diego
and San Francisco, with Takeda California making donations to the
American Diabetes Association to match employee’s distance covered.
The festivities kick off in San Diego with employees biking at Fiesta
Island in Mission Bay, receiving support for repairs and maintenance from
Performance Bikes. In San Francisco, employees will be biking at Coyote
Point Recreation Area in South San Francisco.
Takeda’s involvement with social responsibility is part of Takeda’s
ongoing dedication and commitment to society through corporate social
responsibility activities. Last year, Takeda employee’s involvement and
company donations were able to make a huge impact in San Diego and San
Francisco for several nonprofits committed to helping youth, fighting
cancer, and protecting the environment.
“Our employees are very excited for our second annual Tour de Takeda,
making suggestions of their favorite bike trails,” said Keith Wilson,
Takeda California President. “Collectively, we have an amazing team of
individuals that take pride in aiding our community. Each year we conduct
several company-wide efforts to support local nonprofit organizations,
schools, and the environment.”
PHOTO OPPORTUNITY: SAN DIEGO: Fiesta Island
SAN FRANCISCO: Coyote Point Recreation Area
WHEN: Thursday, March 22, at 9am-1pm
About Takeda California
Takeda California is Takeda's Center of Excellence and Innovation for
Structure-Based Drug Discovery and Protein Therapeutics. The company
combines cutting-edge protein x-ray crystallography, small molecule,
antibody, and antibody drug-conjugate capabilities to efficiently
generate potential new medicines for treating cancer, inflammatory
diseases and metabolic diseases. Multiple potential new drugs invented at
Takeda California are in clinical trials evaluation including NESINA®
(generic name Alogliptin) which was approved for treating patients with
type II diabetes in Japan in 2010.
Takeda California is a wholly owned subsidiary of Takeda Pharmaceutical
Company Limited, one of Japan's largest pharmaceutical companies and one
with a 230-year heritage. Together with its worldwide partners in
science, Takeda California is committed to strive toward better health
for patients through leading innovation in medicine. Additional
information about Takeda California is available through its affiliate
Web site, http://www.takedacalifornia.com.
Located in Osaka, Japan, Takeda is a research-based global company with
its main focus on pharmaceuticals. As one of the largest pharmaceutical
companies in Japan and one of the global leaders of the industry, Takeda
is committed to strive towards better health for patients worldwide
through leading innovation in medicine. Additional information about
Takeda is available through its corporate Web site, www.takeda.com.
Jennifer Von Stauffenberg
Olive PR Solutions, Inc.
350 West Ash Street, #103
San Diego, CA 92101